natgillin/translations-raw huggingface dataset:
How to store Mektovi 6. 
Shranjevanje zdravila Mektovi 6.
The incidences of liver laboratory abnormalities reported in the pooled Combo 450 population are listed below: 
Pojavnosti nenormalnih laboratorijskih izvidov delovanja jeter, poročanih pri združeni populaciji bolnikov v okviru zdravljenja s kombinacijo 450, so navedene spodaj:
Encorafenib + binimetinib n = 192 (Combo 450) 
Enkorafenib + binimetinib n = 192 (Kombinacija 450)
Treatment should continue until the patient no longer derives benefit or the development of unacceptable toxicity. 
Trajanje zdravljenja Zdravljenje naj traja toliko časa, dokler ima bolnik od njega še koristi oziroma dokler se ne razvije nesprejemljiva toksičnost.
• Grade 2 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x - ≤ 5x upper limit of normal (ULN) 
• 2. stopnja aspartat aminotransferaza (AST) ali alanin aminotransferaza (ALT) > 3kratnika-≤ 5-kratnika zgornje meje normalne vrednosti (ULN)
Visual impairment, including vision blurred and reduced visual acuity, occurred in 21.5 % (59/274) of patients. 
Okvara vida, vključno z zamegljenim vidom in zmanjšano ostrino vida, se je pojavila pri 21,5 % (59/274) bolnikov.
A decision must be made whether to discontinue breast-feeding or to discontinue Mektovi therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the mother. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Mektovi, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Binimetinib should be permanently discontinued in patients diagnosed with treatment related pneumonitis or ILD. 
Vnos binimetiniba je treba trajno prekiniti pri bolnikih z diagnozo z zdravljenjem povezane pljučnice ali ILD.
The European Medicines Agency has deferred the obligation to submit the results of studies with binimetinib in one or more subsets of the paediatric population in melanoma (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z enkorafenibom za eno ali več podskupin pediatrične populacije z melanomom (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
What you need to know before you take Mektovi 
Kaj morate vedeti, preden boste vzeli zdravilo Mektovi
Blood pressure should be measured at baseline and monitored during treatment, with control of hypertension by standard therapy as appropriate. 
Izmeriti je treba izhodiščni krvni tlak in ga nato spremljati med zdravljenjem ter po potrebi uvesti standardno terapijo za nadzor hipertenzije.
• sudden shortness of breath or trouble breathing 
• nenadno kratko sapo ali težave z dihanjem,
• Lung or breathing problems: This medicine may cause lung or breathing problems including inflammation of the lungs (pneumonitis or interstitial lung disease); signs and symptoms can include: cough, shortness of breath or fatigue. 
• Težave s pljuči ali dihanjem: To zdravilo lahko povzroči težave s pljuči ali dihanjem, vključno z vnetjem pljuč (pljučnica ali intersticijska pljučna bolezen); znaki in simptomi lahko vključujejo: kašelj, kratko sapo ali utrujenost.
The maximum contribution of direct glucuronidation to the clearance of binimetinib was estimated to have been 61.2 %. 
Neposredna glukuronidacija po ocenah k očistku binimetiniba prispeva največ 61,2-odstotno.
Mektovi is an anti-cancer medicine that contains the active substance binimetinib. 
Mektovi je zdravilo proti raku, ki vsebuje učinkovino binimetinib.
Binimetinib should be withheld for up to 2 weeks and ophthalmic monitoring should be repeated including visual acuity assessment. 
Vnašanje binimetiniba je treba prekiniti za do 2 tedna in ponoviti oftalmološki pregled, vključno z oceno ostrine vida.
In vitro, CYP1A2 and CYP2C19 catalyse the formation of the active metabolite, AR00426032 (M3) by oxidative N-desmethylation. 
In vitro CYP1A2 in CYP2C19 katalizirata pretvorbo v aktivni presnovek AR00426032 (M3) z oksidativno N-demetilacijo.
The incidence of Grade 3 or 4 adverse reactions was 5.8 % (16/274). 
Pojavnost neželenih učinkov 3. ali 4. stopnje je bila 5,8 % (16/274).
The proportion of patients experiencing adverse events and serious adverse events were similar in patients aged <65 years and those aged > 65 years. 
Delež bolnikov, pri katerih je prišlo do neželenih dogodkov in resnih neželenih dogodkov, je podoben pri bolnikih, mlajših od 65 let, in bolnikih, starih 65 let in več.
What Mektovi is and what it is used for 
Kaj je zdravilo Mektovi in za kaj ga uporabljamo
Most events were reported as retinopathy, retinal detachment, subretinal fluid, macular oedema, and chorioretinopathy and led to dose interruptions or dose modifications in 4.7 % (13/274) of patients. 
Večino dogodkov so poročali kot retinopatijo, odstop mrežnice, subretinalno tekočino, makulozni edem in horioretinopatijo ter je povzročila prekinitev vnosa ali spremembo odmerka pri 4,7 % (13/274) bolnikov.
Randomisation was stratified by American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, vs IVM1c) and Eastern Cooperative Oncology Group (ECOG) performance status (0 vs 1) and prior immunotherapy for unresectable or metastatic disease (yes vs no). 
Randomizacija je bila stratificirana po stadijih Ameriškega združenega odbora za raka (AJCC) (IIIB, IIIC, IVM1a ali IVM1b proti IVM1c) in lestvici za ocenjevanje stanja bolnikove zmogljivosti onkološke skupine za preučevanje raka (ECOG) (0 proti 1) ter predhodne imunoterapije za neresektabilno ali metastatsko bolezen (»Da« proti »Ne«).
For patients receiving 45 mg binimetinib twice daily, the recommended reduced dose of binimetinib is 30 mg twice daily. 
Za bolnike, ki prejemajo 45 mg binimetiniba dvakrat dnevno, je priporočeni zmanjšani odmerek binimetiniba 30 mg dvakrat dnevno.
The main route of hepatic transformation of binimetinib being glucoronidation, the decision for treatement should be made by the treating physician taking into account the individual benefit-risk. 
Glavna pot transformacije binimetiniba v jetrih je glukuronidacija, zato se mora za zdravljenje odločiti lečeči zdravnik, pri čemer mora upoštevati razmerje med koristmi in tveganji za posameznika.
Tell your doctor if you have ever had blockage in the vein carrying blood away from the eye (retinal vein occlusion), as Mektovi is not recommended in such cases. 
Če ste kadar koli imeli zaporo v veni, ki odvaja kri iz očesa (zapora mrežnične vene), obvestite zdravnika, saj se zdravilo Mektovi v takih primerih ne priporoča.
• stomach (abdominal) pain 
• bolečine v trebuhu (abdominalne bolečine),
Binimetinib dose should be maintained and it should be ensured that patient is adequately hydrated. 
Nadaljevati je treba z enakim odmerkom binimetiniba in zagotoviti je treba zadostno hidriranost bolnika.
CK and creatinine levels should be monitored monthly during the first 6 months of treatment and as clinically indicated. 
Raven CK in kreatinina je treba v prvih 6 mesecih zdravljenja spremljati enkrat na mesec in kot je klinično indicirano.
• medicine used to treat depression such as duloxetine 
• zdravilo, ki se uporablja za zdravljenje depresije, kot je duloksetin,
Mektovi targets another protein called “MEK” that stimulates cancer cell growth. 
Zdravilo Mektovi deluje na drug protein z imenom »MEK«, ki spodbuja rast rakavih celic.
Part 2 of study CMEK162B2301 was designed to assess the contribution of binimetinib to the encorafenib and binimetinib combination. 
2. del študije CMEK162B2301 je bil zasnovan za ocenjevanje doprinosa, ki ga ima binimetinib v kombinaciji enkorafeniba in binimetiniba.
It is recommended that LVEF is assessed by echocardiogram or multi-gated acquisition (MUGA) scan before initiation of binimetinib, 1 month after initiation, and then at approximately 3-month intervals or more frequently as clinically indicated, while on treatment. 
Priporočeno je, da se LVEF oceni z ehokardiografijo ali slikanjem MUGA (multi-gated acquisition scan) pred začetkom uporabe binimetiniba, 1 mesec po začetku uporabe in nato v približno 3mesečnih intervalih ali pogosteje, kakor je klinično indicirano, v času trajanja terapije.
An analysis of time to definitive 10 % deterioration in EORTC QLQ-C30 score provided with similar results. 
Analiza časa do dokončnega 10-odstotnega poslabšanja po oceni z vprašalnikom EORTC QLQ-C30 je pokazala podobne rezultate.
Hyperkeratosis * 
Hiperkeratoza*
Therefore, binimetinib should be used with caution in these patients. 
Pri teh bolnikih je treba binimetinib uporabljati previdno.
In vitro, CYP1A2 and CYP2C19 catalyse the formation of the active metabolite, which represents less than 20 % of the binimetinib exposure clinically. 
In vitro CYP1A2 in CYP2C19 katalizirata pretvorbo v aktivni presnovek, ki predstavlja manj kot 20 % klinične izpostavljenosti binimetinibu.
Results from a dedicated clinical study with binimetinib only indicate similar exposures in patients with mild impairment (Child-Pugh Class A) and subjects with normal liver function. 
Rezultati namenske klinične študije z binimetinibom kot samostojnim zdravilom nakazujejo podobno izpostavljenost pri bolnikih z blago okvaro (ChildPugh razreda A) in udeležencih z normalno jetrno funkcijo.
Inhibition of P-gp or BCRP is unlikely to result in a clinically important increase in binimetinib concentrations as binimetinib exhibits moderate to high passive permeability. 
P-gp ali BCRP povzročilo klinično pomembno povečanje koncentracij binimetiniba, saj binimetinib izkazuje zmerno do visoko pasivno prepustnost.
Binimetinib treatment in combination with encorafenib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. 
Zdravljenje z binimetinibom v kombinaciji z enkorafenibom mora pričeti in nadzorovati le zdravnik, ki ima izkušnje z uporabo protirakavih zdravil.
The safety of binimetinib has not been established in patients with predisposing factors for RVO including uncontrolled glaucoma, ocular hypertension, uncontrolled diabetes mellitus or a history of hyperviscosity or hypercoagulability syndromes. 
Varnost binimetiniba ni bila dokazana pri bolnikih, ki imajo faktorje tveganja za RVO, vključno z nenadzorovanim glavkomom, očesno hipertenzijo, nenadzorovano sladkorno boleznijo ali anamnezo hiperviskoznega ali hiperkoagulabilnega sindroma.
Standard genotixicity studies with binimetinib were negative. 
Rezultati standardnih študij genotoksičnosti z binimetinibom so bili negativni.
A minimal risk for photosensitisation was shown in vivo at an oral dose providing 3.8-fold higher exposure than that achieved with the recommended dose in humans. 
Pri preskušanjih in vivo se je pokazalo minimalno tveganje za fotosenzibilnost pri peroralnem dajanju zdravila s 3,8-krat večjo izpostavljenostjo, kot je dosežena pri priporočenem odmerku za ljudi.
These data indicate that there is minimal risk for phototoxicity with binimetinib at therapeutic doses in patients. 
Ti podatki kažejo, da pri terapevtskih odmerkih binimetiniba za bolnika obstaja minimalno tveganje za fototoksičnost.
Women of childbearing potential must use effective contraception during treatment with binimetinib and for at least 1 month following the last dose. 
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z binimetinibom in vsaj še 1 mesec po zadnjem odmerku.
Encorafenib n = 194 (Enco 300) 
Enkorafenib n = 194 (Enko 300)
Tell your doctor immediately if you have any of the following serious side effects, either for the first time or if they get worse (see also section 2). 
Nemudoma obvestite zdravnika, če imate katerega od naslednjih resnih neželenih učinkov - če do njih pride prvič ali če se stanje poslabša
If you forget to take Mektovi 
Če ste pozabili vzeti zdravilo Mektovi
Yellow to dark yellow, unscored biconvex, ovaloid film-coated tablets approximately 12 mm in length and 5 mm in width, with the “A” logo debossed on one side of the tablet and “15” on the other side. 
Rumene do temno rumene, bikonveksne, ovalne filmsko obložene tablete brez zareze, dolge približno 12 mm in široke 5 mm, z vtisnjenim logotipom »A« na eni strani tablete in številko »15« na drugi strani.
See section 2 “Mektovi contains lactose”. 
Glejte poglavje 2 »Zdravilo Mektovi vsebuje laktozo«.
Unstratified subgroup analyses demonstrated point estimates in favour of Combo 450, including LDH at baseline, ECOG performance status and AJCC stage. 
Z nestratificiranimi analizami podskupin so se pokazale ocenjene vrednosti v korist kombinaciji 450, vključno z izhodiščno vrednostjo encima LDH, s stanjem zmogljivosti ECOG in stadijem po AJCC.
Binimetinib should be permanently discontinued with the occurrence of RVO (see Table 1 in section 4.2). 
Vnos binimetiniba je treba trajno prekiniti ob pojavu RVO (glejte preglednico 1 v poglavju 4.2).
Cutaneous malignancies such as cutaneous squamous cell carcinoma (cuSCC) including kerathoacanthoma has been observed in patients treated with binimetinib when used in combination with encorafenib. 
Kožne malignosti, kot je ploščatocelični karcinom kože (cuSCC), vključno s keratoakantomom, so opazili pri bolnikih, zdravljenih z binimetinibom v kombinaciji z enkorafenibom.
It is not known if Mektovi passes into breast milk. 
Ni znano, ali zdravilo Mektovi prehaja v materino mleko.
Do not take Mektovi if you are allergic to binimetinib or any of the other ingredients of this medicine (listed in section 6). 
- če ste alergični na binimetinib ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
How to take Mektovi How much to take 
Kako jemati zdravilo Mektovi Koliko zdravila Mektovi vzeti
There are no data from the use of binimetinb in pregnant women. 
Podatkov o uporabi binimetiniba pri nosečnicah ni.
The number of viable foetuses and foetal body weights were reduced and post-implantation loss and resorptions were increased. 
Število fetusov, sposobnih za razvoj, in telesna teža fetusa sta se zmanjšala, povečala pa sta se izguba po implantaciji in resorpcija.
Mektovi is not recommended during pregnancy. 
Zdravilo Mektovi se ne priporoča med nosečnostjo.
• Symptomatic retinal pigment epithelial detachments (RPED) (Grade 2 or 3) 
• Simptomatični odstop mrežničnega pigmentnega epitelija (RPED) (2. ali 3. stopnja)
Treatment with binimetinib should be withheld in patients with suspected pneumonitis or ILD, including patients presenting new or progressive pulmonary symptoms or findings such as cough, dyspnoea, hypoxia, reticular opacities or pulmonary infiltrates (see Table 1 in section 4.2). 
Zdravljenje z binimetinibom je treba prekiniti pri bolnikih, pri katerih sumimo na pljučnico ali ILD, vključno z bolniki, ki kažejo nove ali razvite simptome pljučnih stanj, kot so kašelj, dispneja, hipoksija, retikularna zasenčenja ali pljučna infiltracija (glejte preglednico 1 v poglavju 4.2).
In case of severe hypertension, temporary interruption of binimetinib is recommended until hypertension is controlled (see Table 2 in section 4.2). 
V primeru hude hipertenzije se priporoča začasna prekinitev vnosa binimetiniba, dokler hipertenzija ni spet pod nadzorom (glejte razpredelnico 2 v poglavju 4.2).
In rabbits, mortality, maternal physical signs of toxicity, lower gestational body weight and abortion were noted. 
Pri kuncih so bili zabeleženi umrljivost, fizični znaki toksičnosti pri materi, nižja telesna teža med nosečnostjo in splav.
Results from a dedicated clinical study showed that patients with severe renal impairment (eGFR ≤ 29 mL/min/1.73 m2), had a 29 % increase in exposure (AUCinf), a 21 % increase in Cmax, and a 22 % decrease in CL/F compared to matching healthy subjects. 
Rezultati namenske klinične študije so pokazali, da je v primerjavi z zdravimi udeleženci pri bolnikih s hudo ledvično okvaro (oGF ≤ 29 ml/min/1,73 m2) prišlo do 29-odstotnega povečanja izpostavljenosti (AUCinf), 21-odstotnega povečanja Cmax in 22
• heart problems 
• težave s srcem,
• pain in your legs with or without swelling 
• bolečine v nogah z otekanjem ali brez,
Neuropathy peripheral* 
Periferna nevropatija*
Eye problems: Mektovi can cause fluid to leak under the retina in the eye, leading to detachment of different layers in the eye (retinal pigment epithelial detachment) which could lead to: 
Težave z očmi: Zaradi zdravila Mektovi lahko pride do iztekanja tekočine pod mrežnico v očesu, kar povzroči odstop različnih plasti v očesu (odstop retinalnega pigmentnega epitelija) in lahko privede do:
Patients had histologically confirmed cutaneous or unknown primary melanoma but those with uveal or mucosal melanoma were excluded. 
Bolniki so imeli histološko potrjen kožni ali neznani primarni melanom, bolniki z uvealnim ali mukoznim melanomom pa so bili izključeni.
Part 1 of study CMEK162B2301 demonstrated a statistically significant improvement in PFS in the patients treated with Combo 450 compared with patients treated with vemurafenib. 
1. del študije CMEK162B2301 je pokazal statistično pomembno izboljšanje vrednosti PFS pri bolnikih, zdravljenih s kombinacijo 450, v primerjavi z bolniki, zdravljenimi z vemurafenibom.
Therefore, in these patients, binimetinib should be used with caution and for any symptomatic left ventricular dysfunction, 
Zato je pri teh bolnikih binimetinib treba uporabljati previdno in v primeru simptomatične disfunkcije levega prekata, LVEF
The most common adverse reactions (>25%) occurring in patients treated with encorafenib 300 mg administered with binimetinib were fatigue, nausea and diarrhoea. 
Med najpogostejšimi neželenimi učinki (> 25 %), ki so se pojavili pri bolnikih, zdravljenih z odmerkom 300 mg enkorafeniba, skupaj z binimetinibom, so bili utrujenost, slabost in driska.
Binimetinib is an ATP-uncompetitive, reversible inhibitor of the kinase activity of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. 
Mehanizem delovanja Binimetinib je z ATP nekompetitivni, reverzibilni zaviralec kinazne aktivnosti z mitogenom aktivirane in zunajceličnim signalom regulirane kinaze 1 in 2 (MEK1 in MEK2).
It is used in adults in combination with another medicine containing encorafenib to treat a type of skin cancer called melanoma when it has 
ki vsebuje enkorafenib, se uporablja pri odraslih za zdravljenje vrste kožnega raka, ki se imenuje melanom,
If you stop taking Mektovi 
Če ste prenehali jemati zdravilo Mektovi
Elderly patients No dose adjustment is required for patients aged 65 years and older (see section 5.2). 
Za bolnike, stare 65 let ali več, prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
If a dose of binimetinib is missed, it should not be taken if it is less than 6 hours until the next dose is due. 
Če bolnik pozabi vzeti odmerek binimetiniba, zdravila ne sme vzeti, če je do naslednjega odmerka manj kot 6 ur.
• coughing up of blood or blood clots 
• izkašljevanje krvi ali krvnih strdkov,
New onset elevated blood pressure or worsening of pre-existing hypertension were reported in 11.7 % (32/274) of patients treated with the Combo 450. 
O pojavu novega nastanka zvišanega krvnega tlaka ali o poslabšanju obstoječe hipertenzije so poročali pri 11,7 % (32/274) bolnikov iz združene populacije bolnikov v okviru zdravljenja s kombinacijo 450.
Skin papilloma* 
Kožni papilom*
Talk to your doctor, pharmacist or nurse before taking Mektovi about all of your medical conditions, particularly if you have any of the following: 
Pred začetkom jemanja zdravila Mektovi se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro o svojem zdravstvenem stanju, zlasti če imate katero koli od naslednjih stanj:
Based on a population pharmacokinetic (PK) analysis, the PK of binimetinib were similar in males as compared with females. 
Glede na populacijsko farmakokinetično (FK) analizo je FK binimetiniba podobna pri moških in ženskah.
27 patients (5 %) had received prior checkpoint inhibitors (antiPD1/PDL1 or ipilimumab) (8 patients in Combo 450 arm (4 %); 7 patients in vemurafenib arm (4 %); 12 patients in Enco 300 arm (6 %) including 22 patients in the metastatic setting (6 patients in Combo 450 arm; 5 patients in vemurafenib arm; 11 patients in Enco 300 arm) and 5 patients in the adjuvant setting (2 patients in Combo 450 arm; 2 patients in vemurafenib arm; 1 patient in Enco 300 arm. 
27 bolnikov (5 %) je predhodno prejelo predhodno imunoterapijo (antiPD1/PDL1 ali ipilimumab) (8 bolnikov pri kombinaciji 450 (4 %); 7 bolnikov pri vemurafenibu (4 %); 12 bolnikov pri Enko 300 (6 %), vključno z 22 bolniki z metastatsko boleznijo (6 bolnikov pri kombinaciji 450, 5 bolnikov pri vemurafenibu, 11 bolnikov pri Enko 300) in 5 bolniki v okviru adjuvantnega zdravljenja (2 bolnika pri kombinaciji 450, 2 bolnika pri vemurafenibu, 1 bolnik pri Enko 300).
Binimetinib is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Zdravila binimetinib ni priporočljivo uporabljati pri nosečnicah in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
In patients treated with Combo 450 (n = 274), 194 patients (70.8 %) were < 65 years old, 65 patients (23.7 %) were 65 -74 years old and 15 patients (5.5 %) were aged > 75. 
Pri bolnikih v okviru zdravljenja s kombinacijo 450 (n = 274) je bilo 194 bolnikov (70,8 %) mlajših od 65 let, 65 bolnikov (23,7 %) je bilo starih med 65 in 74 let, 15 bolnikov (5,5 %) pa je bilo starejših od 75 let.
Liver metabolism mainly via glucuronidation is the primary route of elimination of binimetinib (see section 5.2). 
Presnova v jetrih, zlasti glukuronidacija, je primarna pot izločanja binimetiniba (glejte poglavje 5.2).
Study CMEK162B2301, Part 2 
Študija CMEK162B2301, 2.del
The most common adverse events reported with a higher incidence in patients aged ≥ 65 years compared to patients aged < 65 years included diarrhoea, pruritus, GGT and blood phosphatase alkaline elevation. 
Najpogostejši neželeni dogodki, o katerih so pogosteje poročali pri bolnikih, starih 65 let in več, v primerjavi z bolniki, mlajšimi od 65 let, so vključevali drisko, srbenje, zvišano vrednost GGT in zvišano vrednost alkalne fosfataze v krvi.
Tell your doctor immediately if you detect any skin changes during and after the treatment including: new wart, skin sore or reddish bump that bleeds or does not heal, or a change in size or colour of a mole. 
Zdravnika nemudoma obvestite, če med zdravljenjem ali po njem opazite kakršne koli spremembe na koži, vključno z novim izrastkom, rano na koži ali rdečkasto buško, iz katere krvavite ali ki se ne zaceli, ali spremembo velikosti ali barve materinega znamenja.
• headaches, dizziness or weakness 
• glavoboli, vrtoglavica ali oslabelost,
If binimetinib is used during pregnancy, or if the patient becomes pregnant while taking binimetinib, the patient should be informed of the potential hazard to the foetus. 
Če bolnica jemlje binimetinib med nosečnostjo ali med jemanjem binimetiniba zanosi, jo je treba opozoriti o možni nevarnosti za plod.
Venous thromboembolism (VTE) 
Venski tromboembolizem (VTE)
Binimetinib and encorafenib should be continued without any dose modifications. 
Jemanje binimetiniba in enkorafeniba je treba nadaljevati z nespremenjenim odmerkom.
Hypertension events were reported as Grade 3 in 5.5 % (15/274) of patients, including hypertensive crisis (0.4 % (1/274)). 
Hipertenzija je bila poročana kot dogodek 3. stopnje pri 5,5 % (15/274) bolnikov, vključno s hipertenzivno krizo (0,4 % (1/274)).
Tell your doctor if you have had a different type of cancer than melanoma, as binimetinib when taken with encorafenib may worsen certain other types of cancers. 
Če ste že imeli vrsto raka, ki ni melanom, obvestite zdravnika, saj jemanje binimetiniba z enkorafenibom lahko poslabša stanje nekaterih drugih vrst raka.
In addition, simulations to investigate the effect of 400 mg atazanavir (UGT1A1 inhibitor) on the exposure of 45 mg binimetinib predicted similar binimetinib Cmax in the presence or absence of atazanavir. 
Poleg tega so s pomočjo simulacij za raziskavo učinka 400 mg atazanavira (zaviralec UGT1A1) na izpostavljenost 45 mg binimetiniba napovedali podobno najvišjo koncentracijo Cmax binimetiniba, ne glede na prisotnost oziroma odsotnost atazanivira.
Binimetinib is to be given in combination with encorafenib. 
Binimetinib je treba jemati v kombinaciji z enkorafenibom.